Regeneron Pharmaceuticals, Inc.

BVL:REGN Stock Report

Market Cap: US$75.5b

Regeneron Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

BVL:REGN Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
28 Aug 24SellUS$6,363,588Christopher FenimoreIndividual5,280US$1,206.30
28 Aug 24SellUS$482,674Christopher FenimoreIndividual400US$1,206.70
08 Aug 24SellUS$5,636,346Neil StahlIndividual5,197US$1,086.15
26 Feb 24SellUS$990,000Joseph LaRosaIndividual1,000US$990.00
22 Feb 24SellUS$967,650Joseph LaRosaIndividual1,000US$967.65
14 Feb 24SellUS$9,831,727Daniel Van PlewIndividual10,434US$951.77
09 Feb 24SellUS$4,689,320Christopher FenimoreIndividual4,919US$955.00
07 Feb 24SellUS$7,637,954Neil StahlIndividual8,037US$953.00
07 Feb 24SellUS$950,000Joseph LaRosaIndividual1,000US$950.00
05 Feb 24SellUS$934,710Marion McCourtIndividual1,000US$934.71

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of REGN?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2700.000251%
State or Government119,0910.111%
Individual Insiders4,320,9554.02%
General Public7,900,0807.34%
Institutions95,249,13588.5%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 64.71% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.28%
FMR LLC
9,989,118US$7.0b-2.97%0.42%
8.66%
The Vanguard Group, Inc.
9,320,290US$6.5b3.63%0.1%
7.96%
Capital Research and Management Company
8,562,198US$6.0b-0.24%0.29%
7.88%
BlackRock, Inc.
8,480,262US$6.0b0.4%0.1%
5.97%
JP Morgan Asset Management
6,427,659US$4.5b-10.1%0.51%
4.56%
State Street Global Advisors, Inc.
4,902,404US$3.4b1.27%0.13%
2.23%
Leonard Schleifer
2,395,911US$1.7b0%no data
2.15%
Dodge & Cox
2,311,935US$1.6b-0.16%0.56%
2.11%
Geode Capital Management, LLC
2,272,261US$1.6b-5.92%0.11%
1.33%
Putnam LLC
1,432,757US$1.0b-2.29%0.97%
1.19%
T. Rowe Price Group, Inc.
1,275,303US$895.1m36.7%0.08%
1.1%
Loomis Sayles & Company, L.P.
1,181,352US$829.1m-2.92%1.0%
1.07%
George Yancopoulos
1,153,695US$809.7m0%no data
1.05%
Norges Bank Investment Management
1,126,948US$790.9m0%0.06%
1%
Amundi Asset Management SAS
1,079,023US$757.3m1.18%0.16%
0.95%
UBS Asset Management AG
1,026,962US$720.8m-6.82%0.07%
0.89%
Legal & General Investment Management Limited
959,127US$673.2m-1.94%0.12%
0.85%
Northern Trust Global Investments
918,645US$644.7m-4.97%0.1%
0.69%
American Century Investment Management Inc
738,495US$518.3m-10.6%0.25%
0.67%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
722,045US$506.8m-5.06%0.13%
0.66%
BNY Asset Management
706,789US$496.1m-17.4%0.1%
0.63%
Charles Schwab Investment Management, Inc.
673,261US$472.5m1.74%0.08%
0.62%
Teachers Insurance and Annuity Association-College Retirement Equities Fund
669,066US$469.6m14.1%0.11%
0.62%
Invesco Capital Management LLC
666,982US$468.1m32.2%0.19%
0.59%
Morgan Stanley, Investment Banking and Brokerage Investments
630,259US$442.3m-22.1%0.05%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 08:33
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 70 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research